Neuromuscular Junction Management for Anesthesia

Patient Selection and Agent Choice

For patients with renal or hepatic failure, benzylisoquinoline muscle relaxants, such as atracurium or cisatracurium, are the recommended choice due to organ-independent elimination, as stated by the Anaesthesia guideline society 1, 2, 3
Atracurium undergoes approximately 50% elimination via organ-independent Hofmann degradation and ester hydrolysis, with unchanged pharmacokinetics in renal and hepatic failure, according to the Anaesthesia guideline society 1, 2
Cisatracurium is preferred over atracurium because it is more potent, requiring lower doses and generating significantly less laudanosine metabolite, as recommended by the Anaesthesia guideline society 1, 2, 3

Quantitative neuromuscular monitoring using train-of-four (TOF) stimulation is essential to determine timing of reversal and adequacy of recovery, as stated by the Anaesthesia guideline society 4, 3
Post-tetanic count (PTC) is used to assess very deep blockade when no TOF responses are present, according to the Anaesthesia guideline society 4
Neostigmine can only reverse moderate blockade (when ≥2 TOF responses are present) and requires 10-30 minutes to achieve TOF ratio ≥0.9, as stated by the Anaesthesia guideline society 4
Sugammadex provides rapid, dose-dependent reversal of rocuronium and vecuronium based on blockade depth, with efficacy in 3-5 minutes, according to the Anaesthesia guideline society 4

For patients with neuromuscular disease, sugammadex is strongly preferred over neostigmine for reversal of steroidal muscle relaxants, as recommended by the Anaesthesia guideline society 1
In renal failure, sugammadex can be administered at usual doses despite lack of renal elimination, according to the Praxis Medical Insights guideline society 2